[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Synthes, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":80},{"warningLetters":4,"total":79},[5,34,58],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":29,"recipient_name":30,"body_fetched_at":31,"delivery_method":32,"recipient_title":20,"reference_number":20,"action_taken_date":33,"medical_device_id":20,"response_letter_date":20},2361,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2022-11-08T14:20:00Z\">11\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-06T04:00:00Z\">09\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthird-synthesis-inc-dba-chicago-sweet-connections-inc-633453-09062022\">Third Synthesis Inc., dba Chicago Sweet Connections, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","CGMP\u002FManufacturing, Packing or Holding Human Food\u002FAdulterated\u002FInsanitary Conditions","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthird-synthesis-inc-dba-chicago-sweet-connections-inc-633453-05252023\">\u003Ctime datetime=\"2023-06-02T04:00:00Z\">06\u002F02\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Anthanasios Kailis\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Third Synthesis Inc., dba Chicago Sweet Connections, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5569 N. Northwest Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chicago\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60630\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nFY22-HAFE6-WL-06 CMS 633453\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 6, 2022\u003Cbr>\n\u003Cbr>\nDear Mr. Kailis:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your bakery facility located at 5569 N. Northwest Highway, Chicago, IL from February 24, 2022 through March 24, 2022, and on May 3, 2022, FDA investigators returned to your facility to collect further documentation and product labeling. During the inspection, FDA investigators found serious violations, described below, of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). At the conclusion of the inspection, FDA issued an FDA Form 483, Inspectional Observations, listing violations found at your facility.\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the ready-to-eat (RTE) cakes and paczkis manufactured in your facility are adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United States Codes (U.S.C.) § 342(a)(4)] because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by Section 301(uu) of the Act [21 U.S.C. § 331(uu)].\u003C\u002Fp>\n\n\u003Cp>Additionally, we reviewed product labels collected during our inspection. Based on our review, we concluded that certain products are in violation of section 403 of the Act [21 U.S.C. § 343], as described further in this letter. You can find the Act and FDA’s regulations through internet links in FDA's website at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>During the course of the inspection, FDA investigators observed several types of paczkis and coffee cakes which did not declare allergens, including wheat, milk and\u002For egg. These products were recalled by your firm on February 25, 2022.\u003C\u002Fp>\n\n\u003Cp>We received your written response dated April 13, 2022, which included a summary of corrective actions by your facility. After reviewing the inspectional findings and your response to the observations listed in the FDA Form 483, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We address your response below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You did not appropriately evaluate known or reasonably foreseeable hazards to determine whether there are any hazards requiring a preventive control for your RTE cakes and paczkis, as required by 21 CFR 117.130(a)(1). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Your hazard analysis considered undeclared allergens at the packaging\u002Flabeling step, but determined that this hazard was not “Significant” (i.e., did not require a preventive control) because “[a]ll products contain wheat, milk, egg and soy which are known allergens. Products containing nuts or coconut, contain a unique allergen, tree nuts.” However, your facility receives, stores, and uses allergens such as wheat, milk, egg, soy, and tree nuts (including walnuts, pecans, and coconut) in production. Therefore, undeclared allergens are a known or reasonably foreseeable hazard. Further, a knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify undeclared allergens as a hazard requiring a preventive control. Preventive controls for food allergens include procedures, practices, and processes employed for labeling to ensure that all food allergens are included on the label (see 21 CFR 117.135(c)(2)(ii)).\u003C\u002Fp>\n\n\u003Cp>We note that you had an allergen control program, “Allergen Control Program No: CSCB-208.\" However, you did not have adequate allergen controls in place as evidenced by your February 25, 2022 recall of paczkis and coffee cakes which did not declare allergens including wheat, milk and\u002For egg. Further, your allergen control program did not adequately address the monitoring of labels. The program stated that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” This procedure did not adequately address monitoring because it does not specify the number of finished products that will be monitored or establish the frequency with which this monitoring is to be performed (see 21 CFR 117.145(a)). Additionally, you did not implement this procedure. FDA investigators observed pre-printed labels being applied to products by a label operator who also checked that the right label was applied to the product. However, there was no “inspect[ion] by QA” and no checking that there was “proper labeling of allergenic products … in the label ingredient statement.”\u003C\u002Fp>\n\n\u003Cp>Furthermore, as mentioned above, FDA investigators observed several types of paczkis and coffee cakes which did not declare allergens, including wheat, milk and\u002For egg. These products were recalled by your firm on February 25, 2022.Your response stated that fresh finished product bakery item labels will be reviewed on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis and that QA is not always available to check the variety of products that are being packed and labeled. However, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> review of labels is not adequate to ensure that allergens are correctly declared on your product labels and that the right label is applied during production.\u003C\u002Fp>\n\n\u003Cp>b. Your hazard analysis considered allergen cross-contact at the setup and packaging\u002Flabeling steps, but determined that this hazard did not require a preventive control because your “Sanitation SOP” made contamination via equipment and workers unlikely. However, preventive controls for food allergens include procedures, practices, and processes employed for ensuring protection of food from allergen cross-contact, e.g., SSOPs such as your Sanitation SOP referenced above (see 21 CFR 117.135(c)(2)(i)). Thus, we would consider controls within this program to be preventive controls for allergens and not an appropriate basis to conclude that preventive controls are not needed. Further, your hazard analysis did not consider allergen cross-contact at the cake slicing and finishing\u002Ficing steps. You manufacture cakes with different allergen profiles on the same day on shared equipment at these steps. Allergen cross-contact could occur in products with different allergen profiles, without appropriate controls. Therefore, allergen cross-contact is a known or reasonably foreseeable hazard. Further, a knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify allergen cross-contact as a hazard requiring a preventive control.\u003C\u002Fp>\n\n\u003Cp>We note that although you had an allergen control program, it did not adequately address cross contact. Your program stated that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, this procedure is not adequate as a preventive control for allergen cross-contact because it lacks monitoring and\u002For verification procedures and addresses the cleaning and sanitizing of machines but not of other food-contact equipment such as spatulas, frosting platforms, and prep tables. Further, the procedure does not distinguish between allergen-containing products with different allergen profiles (e.g., two products, both containing allergens, but one contains a unique tree nut allergen).\u003C\u002Fp>\n\n\u003Cp>The failure to account for foods with different allergen profiles was evident on March 1, 2022, when FDA investigators observed the manufacture of 10” Carrot Cakes (containing the allergens wheat, egg, milk, soy, and walnuts in the cooked sponge cake) and the manufacture of 10” Red Velvet Cakes (containing the allergens wheat, egg, milk, and soy). Carrot Cakes were scheduled before Red Velvet Cakes, despite the Carrot Cakes containing the unique walnut allergen. Further, FDA investigators observed an employee roll a rack of unfrosted Carrot Cakes next to the conveyor belt line. An employee at the beginning of the line used their gloved hands to grab the sides of the Carrot Cakes and transfer them to a platform for frosting. After the Carrot Cakes were frosted by a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the employee used their gloved hands to place them onto the conveyor belt line. A different employee (one of several) then removed the Carrot Cakes from the line and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to an adjacent prep table where the cream cheese frosting was smoothed using a flat, long spatula. The employees also added additional cream cheese frosting as needed from a \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the table, using the spatula. On the same day, immediately after frosting your Carrot Cakes (which contained walnuts in the cake), the original employee, using the same gloves, switched to transferring the Red Velvet Cakes (not containing walnuts) to the frosting platform without washing the frosting platform, washing their hands, or changing gloves. These Red Velvet Cakes were then also moved from the conveyor line to the prep table for additional frosting and smoothing. The employees performed the final frosting with the same spatula, without cleaning the spatula between products, and dipped the spatulas into the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> that had been used for the Carrot Cake.\u003C\u002Fp>\n\n\u003Cp>Your response stated that you are now running any products that contain allergens last in your production schedule. However, your response did not provide an updated production schedule, batch record, or monitoring records to demonstrate implementation. Also, your response did not elaborate how you sequence allergen-containing products with different allergen profiles (e.g., sequencing among products with various unique tree nut allergens). Finally, your response did not provide details of when and how cleaning of food-contact equipment will be performed between products with different allergen profiles.\u003C\u002Fp>\n\n\u003Cp>c. Your hazard analysis considered pathogen contamination via equipment and workers at the cooling\u002Fdepanning, cake slicing, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, setup, and packaging\u002Flabeling steps, but determined that this hazard did not require a preventive control because “SSOP makes contamination via equipment and workers unlikely.” However, sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR 117.135(c)(3)). Thus, we would consider controls within this program to be preventive controls for pathogens and not an appropriate basis to conclude that preventive controls are not needed. In addition, your hazard analysis did not consider pathogen contamination at the finishing\u002Ficing step. Your RTE cakes are exposed to the environment after being baked and until they are packaged. The packaged cakes do not receive a lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize pathogens. Therefore, contamination with environmental pathogens is a known or reasonably foreseeable hazard. Further, a knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify environmental pathogens as a hazard requiring a preventive control (i.e., sanitation controls).\u003C\u002Fp>\n\n\u003Cp>We note that although your sanitation SOP included environmental monitoring, you did not implement this aspect of the SOP. Specifically, your SOP stated that “QA member will conduct environmental swab[bing] [for] Listeria and Salmonella [] \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” During the inspection, your Director of Operations stated that the facility does not collect environmental swabs for \u003Cem>Listeria, Salmonella\u003C\u002Fem>, or any target organism.\u003C\u002Fp>\n\n\u003Cp>Your response stated that you updated your sanitation SOP to include performing environmental monitoring \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide the updated sanitation procedure or documentation to show that you are collecting environmental samples at your facility. We have reached out to you requesting supporting documentation and have not received a response to date.\u003C\u002Fp>\n\n\u003Cp>d. Your hazard analysis did not identify and evaluate mycotoxins as a known or reasonably foreseeable hazard to determine whether they require a preventive control. Your facility manufactures cakes with walnuts, wheat flour, and raisins (e.g., Carrot Cake). These ingredients have been associated with mycotoxins. Therefore, contamination with mycotoxins is a known or reasonably foreseeable hazard. Further, a knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify mycotoxins as a hazard in ingredients that requires a supply-chain-applied control (i.e., the hazard is associated with an ingredient and is controlled before receipt of the ingredient) and would establish and implement a risk-based supply-chain program for those raw materials and other ingredients (see 21 CFR § 117.405(a)(1)). The supply-chain program must include using approved suppliers and conducting supplier verification activities (see 21 CFR § 117.410). We note that you had a receiving procedure, “Receiving Raw Materials Document No: SOP-101,\" but it did not address the use of approved suppliers (see 21 CFR 117.415(a)(1)), and you did not approve suppliers.\u003C\u002Fp>\n\n\u003Cp>Your response stated that you have included mycotoxins in your hazard analysis, that your suppliers will include mycotoxins as part of the COAs they send to you, and if their COAs do not include mycotoxin results, they will send you a letter of guarantee \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide an updated hazard analysis, receiving procedure, or implementation records. Also, note that an \u003Cstrong>(b)(4)\u003C\u002Fstrong> guarantee alone would not be an adequate verification activity to ensure that a supplier is controlling the hazard of mycotoxins because it does not include, among other things, actual analytical results from sampling and testing.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (21 CFR Part 117, Subpart B):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>2. You did not store or transport food, including ingredients, under conditions that protect against allergen cross-contact to comply with 21 CFR 117.93. Specifically, on March 1, 2022, in the finished product walk-in refrigerator, FDA investigators observed the storage of finished, unpackaged 10” cakes. The cakes were stored on racks with \u003Cstrong>(b)(4)\u003C\u002Fstrong> shelving. Cakes with coconut shavings (coconut allergen) were observed stored above lemon cakes that did not contain coconut or other tree nuts. FDA investigators also observed cake toppings stored in individual plastic trays, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> tall, on a rolling speed rack. Each topping had a loose piece of parchment paper placed on top it. The tray of chopped walnuts ( an allergen) was in the middle of the rack, stored above other non-nut containing toppings such as Oreo crumbles, rainbow sprinkles, red velvet cake crumbles, and yellow cake crumbles.\u003C\u002Fp>\n\n\u003Cp>Your response stated that you have a dedicated rolling rack for allergens and that cakes that contain allergens must be fully packaged upon completion; however, you have not provided any documentation that these corrective actions have been implemented. We have reached out to you requesting supporting documentation and have not received a response to date.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Your Blueberry Coffee Cake and Carrot Cake 10” products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. 343(i)(2)] because they are fabricated from two or more ingredients and the labels fail to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your Blueberry Coffee Cake:\u003Cbr>\n&nbsp; i. The labels fail to declare \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an ingredient in your blueberry filling ingredient.\u003Cbr>\n&nbsp; ii. The label does not bear the statement: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” as required by 21 CFR 172.804(d)(2).\u003Cbr>\n&nbsp; iii. The ingredients “Syrus” and “Fondandt” are misspelled, and the flour ingredient “flour unbleached prepared flour” is not an appropriate declaration for a flour ingredient.\u003C\u002Fp>\n\n\u003Cp>b. Your Apple Coffee Cake:\u003Cbr>\n&nbsp; i. The ingredients “Shortening Hydrogenated Soybean &amp; Cottonseed,” “Flourenhanced” are not the appropriate common or usual names for these ingredients as required under 21 CFR 101.4(a). The terms “Artifical,” “USF&amp;D,” “Syrus,” “Fondandt,” “Riboflavor,” and “Propul” are misspelled.\u003Cbr>\n\u003Cbr>\nc. Your Carrot Cake 10” label lists cream cheese and its subingredients, which is not used in the product, but fails to list the ingredients in the milk and cheese culture blend that is used in the product. The requirement to list these component ingredients (or “sub-ingredients”) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient, or by listing the component ingredients without listing the ingredient itself. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi-component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\u003C\u002Fp>\n\n\u003Cp>d. Your Custard Bundt Cake label lists the ingredient “N&amp;A Flavor,” which is not the appropriate common or usual name of an ingredient, as required by 21 CFR 101.4(a).\u003C\u002Fp>\n\n\u003Cp>2. Your Custard Bundt Cakes, Paczki, and Coffee Cakes are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. §343(q)] because they do not comply with the requirements in 21 CFR 101.9. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Your Custard Bundt Cake:\u003Cbr>\n&nbsp; i. The serving size is listed as 1 serving (136g). The appropriate Reference Amount Customarily Consumed Per Eating Occasion (RACC) for the product is 80 g\u002Ffractional slice for large discrete units in accordance with 21 CFR 101.12(b) – Table 2 – Medium weight cakes.\u003Cbr>\n&nbsp; ii. The serving size is not expressed in common household measures as required by 21 CFR 101.9(b)(7).\u003C\u002Fp>\n\n\u003Cp>b. Your Cheese Paczki, Blueberry Coffee Cake, and Apple Coffee Cake labels fail to bear nutrition information; i.e., a Nutrition Facts label, as required by 21 CFR 101.9(a). Your firm may qualify for a Small Business Nutrition Labeling Exemption, but as of 6\u002F27\u002F2022, your firm has not filed for the exemption.\u003C\u002Fp>\n\n\u003Cp>3. Your Custard Bundt Cakes are misbranded within the meaning of section 403(k) of the Act [21 U.S.C. §343(k)]. Specifically, the label declares the ingredients sodium benzoate and potassium sorbate, which are chemical preservatives in accordance with 21 CFR 184.1733 and 182.3640, respectively, and the descriptor of the function of these two ingredients is missing. In accordance with 21 CFR 101.22(j), a food to which a chemical preservative(s) is added must include a separate description of its function, e.g., “preservative”, “to retard spoilage”, “a mold inhibitor”, “to help protect flavor” or “to promote color retention”.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to do so may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comment for your Custard Bundt cake label: we note that as a fabricated food, most sugars would not be considered naturally occurring; almost all sugars would be added sugars.\u003C\u002Fp>\n\n\u003Cp>In your Ingredient statement the first ingredient is sugar, and the Nutrition Facts Label’s added sugar declaration states “37g Total Sugars” but “&lt; 1g Added Sugars.” Information about food labeling, including nutrition labeling and nutrition labeling exemptions, can be found at the following link: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-labeling-nutrition\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-labeling-nutrition\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act or that you have complied with FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Lauren Crivellone, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov or at 550 West Jackson Boulevard, Chicago, IL 60661. You may reach Ms. Crivellone at 312-206-5264 or via email at Lauren.Crivellone @fda.hhs.gov if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nWilliam R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nDivision East 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAnthanasios Kailis\n\nRecipient Title\n\nPresident\u002FCEO\u002FOwner\n\nThird Synthesis Inc., dba Chicago Sweet Connections, Inc.\n\n5569 N. Northwest Highway\n\nChicago, IL 60630\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nWARNING LETTER\n\nFY22-HAFE6-WL-06 CMS 633453\n\nSeptember 6, 2022\n\nDear Mr. Kailis:\n\nThe United States Food and Drug Administration (FDA) inspected your bakery facility located at 5569 N. Northwest Highway, Chicago, IL from February 24, 2022 through March 24, 2022, and on May 3, 2022, FDA investigators returned to your facility to collect further documentation and product labeling. During the inspection, FDA investigators found serious violations, described below, of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). At the conclusion of the inspection, FDA issued an FDA Form 483, Inspectional Observations, listing violations found at your facility.\n\nBased on FDA’s inspectional findings, we have determined that the ready-to-eat (RTE) cakes and paczkis manufactured in your facility are adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United States Codes (U.S.C.) § 342(a)(4)] because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by Section 301(uu) of the Act [21 U.S.C. § 331(uu)].\n\nAdditionally, we reviewed product labels collected during our inspection. Based on our review, we concluded that certain products are in violation of section 403 of the Act [21 U.S.C. § 343], as described further in this letter. You can find the Act and FDA’s regulations through internet links in FDA's website at http:\u002F\u002Fwww.fda.gov.\n\nDuring the course of the inspection, FDA investigators observed several types of paczkis and coffee cakes which did not declare allergens, including wheat, milk and\u002For egg. These products were recalled by your firm on February 25, 2022.\n\nWe received your written response dated April 13, 2022, which included a summary of corrective actions by your facility. After reviewing the inspectional findings and your response to the observations listed in the FDA Form 483, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We address your response below.\n\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C):\n\n1. You did not appropriately evaluate known or reasonably foreseeable hazards to determine whether there are any hazards requiring a preventive control for your RTE cakes and paczkis, as required by 21 CFR 117.130(a)(1). Specifically:\n\na. Your hazard analysis considered undeclared allergens at the packaging\u002Flabeling step, but determined that this hazard was not “Significant” (i.e., did not require a preventive control) because “[a]ll products contain wheat, milk, egg and soy which are known allergens. Products containing nuts or coconut, contain a unique allergen, tree nuts.” However, your facility receives, stores, and uses allergens such as wheat, milk, egg, soy, and tree nuts (including walnuts, pecans, and coconut) in production. Therefore, undeclared allergens are a known or reasonably foreseeable hazard. Further, a knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify undeclared allergens as a hazard requiring a preventive control. Preventive controls for food allergens include procedures, practices, and processes employed for labeling to ensure that all food allergens are included on the label (see 21 CFR 117.135(c)(2)(ii)).\n\nWe note that you had an allergen control program, “Allergen Control Program No: CSCB-208.\" However, you did not have adequate allergen controls in place as evidenced by your February 25, 2022 recall of paczkis and coffee cakes which did not declare allergens including wheat, milk and\u002For egg. Further, your allergen control program did not adequately address the monitoring of labels. The program stated that “(b)(4).” This procedure did not adequately address monitoring because it does not specify the number of finished products that will be monitored or establish the frequency with which this monitoring is to be performed (see 21 CFR 117.145(a)). Additionally, you did not implement this procedure. FDA investigators observed pre-printed labels being applied to products by a label operator who also checked that the right label was applied to the product. However, there was no “inspect[ion] by QA” and no checking that there was “proper labeling of allergenic products … in the label ingredient statement.”\n\nFurthermore, as mentioned above, FDA investigators observed several types of paczkis and coffee cakes which did not declare allergens, including wheat, milk and\u002For egg. These products were recalled by your firm on February 25, 2022.Your response stated that fresh finished product bakery item labels will be reviewed on a (b)(4) basis and that QA is not always available to check the variety of products that are being packed and labeled. However, a (b)(4) review of labels is not adequate to ensure that allergens are correctly declared on your product labels and that the right label is applied during production.\n\nb. Your hazard analysis considered allergen cross-contact at the setup and packaging\u002Flabeling steps, but determined that this hazard did not require a preventive control because your “Sanitation SOP” made contamination via equipment and workers unlikely. However, preventive controls for food allergens include procedures, practices, and processes employed for ensuring protection of food from allergen cross-contact, e.g., SSOPs such as your Sanitation SOP referenced above (see 21 CFR 117.135(c)(2)(i)). Thus, we would consider controls within this program to be preventive controls for allergens and not an appropriate basis to conclude that preventive controls are not needed. Further, your hazard analysis did not consider allergen cross-contact at the cake slicing and finishing\u002Ficing steps. You manufacture cakes with different allergen profiles on the same day on shared equipment at these steps. Allergen cross-contact could occur in products with different allergen profiles, without appropriate controls. Therefore, allergen cross-contact is a known or reasonably foreseeable hazard. Further, a knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify allergen cross-contact as a hazard requiring a preventive control.\n\nWe note that although you had an allergen control program, it did not adequately address cross contact. Your program stated that “(b)(4).” However, this procedure is not adequate as a preventive control for allergen cross-contact because it lacks monitoring and\u002For verification procedures and addresses the cleaning and sanitizing of machines but not of other food-contact equipment such as spatulas, frosting platforms, and prep tables. Further, the procedure does not distinguish between allergen-containing products with different allergen profiles (e.g., two products, both containing allergens, but one contains a unique tree nut allergen).\n\nThe failure to account for foods with different allergen profiles was evident on March 1, 2022, when FDA investigators observed the manufacture of 10” Carrot Cakes (containing the allergens wheat, egg, milk, soy, and walnuts in the cooked sponge cake) and the manufacture of 10” Red Velvet Cakes (containing the allergens wheat, egg, milk, and soy). Carrot Cakes were scheduled before Red Velvet Cakes, despite the Carrot Cakes containing the unique walnut allergen. Further, FDA investigators observed an employee roll a rack of unfrosted Carrot Cakes next to the conveyor belt line. An employee at the beginning of the line used their gloved hands to grab the sides of the Carrot Cakes and transfer them to a platform for frosting. After the Carrot Cakes were frosted by a (b)(4), the employee used their gloved hands to place them onto the conveyor belt line. A different employee (one of several) then removed the Carrot Cakes from the line and (b)(4) to an adjacent prep table where the cream cheese frosting was smoothed using a flat, long spatula. The employees also added additional cream cheese frosting as needed from a (b)(4) on the table, using the spatula. On the same day, immediately after frosting your Carrot Cakes (which contained walnuts in the cake), the original employee, using the same gloves, switched to transferring the Red Velvet Cakes (not containing walnuts) to the frosting platform without washing the frosting platform, washing their hands, or changing gloves. These Red Velvet Cakes were then also moved from the conveyor line to the prep table for additional frosting and smoothing. The employees performed the final frosting with the same spatula, without cleaning the spatula between products, and dipped the spatulas into the same (b)(4) that had been used for the Carrot Cake.\n\nYour response stated that you are now running any products that contain allergens last in your production schedule. However, your response did not provide an updated production schedule, batch record, or monitoring records to demonstrate implementation. Also, your response did not elaborate how you sequence allergen-containing products with different allergen profiles (e.g., sequencing among products with various unique tree nut allergens). Finally, your response did not provide details of when and how cleaning of food-contact equipment will be performed between products with different allergen profiles.\n\nc. Your hazard analysis considered pathogen contamination via equipment and workers at the cooling\u002Fdepanning, cake slicing, (b)(4), setup, and packaging\u002Flabeling steps, but determined that this hazard did not require a preventive control because “SSOP makes contamination via equipment and workers unlikely.” However, sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR 117.135(c)(3)). Thus, we would consider controls within this program to be preventive controls for pathogens and not an appropriate basis to conclude that preventive controls are not needed. In addition, your hazard analysis did not consider pathogen contamination at the finishing\u002Ficing step. Your RTE cakes are exposed to the environment after being baked and until they are packaged. The packaged cakes do not receive a lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize pathogens. Therefore, contamination with environmental pathogens is a known or reasonably foreseeable hazard. Further, a knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify environmental pathogens as a hazard requiring a preventive control (i.e., sanitation controls).\n\nWe note that although your sanitation SOP included environmental monitoring, you did not implement this aspect of the SOP. Specifically, your SOP stated that “QA member will conduct environmental swab[bing] [for] Listeria and Salmonella [] (b)(4).” During the inspection, your Director of Operations stated that the facility does not collect environmental swabs for Listeria, Salmonella, or any target organism.\n\nYour response stated that you updated your sanitation SOP to include performing environmental monitoring (b)(4). However, you did not provide the updated sanitation procedure or documentation to show that you are collecting environmental samples at your facility. We have reached out to you requesting supporting documentation and have not received a response to date.\n\nd. Your hazard analysis did not identify and evaluate mycotoxins as a known or reasonably foreseeable hazard to determine whether they require a preventive control. Your facility manufactures cakes with walnuts, wheat flour, and raisins (e.g., Carrot Cake). These ingredients have been associated with mycotoxins. Therefore, contamination with mycotoxins is a known or reasonably foreseeable hazard. Further, a knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify mycotoxins as a hazard in ingredients that requires a supply-chain-applied control (i.e., the hazard is associated with an ingredient and is controlled before receipt of the ingredient) and would establish and implement a risk-based supply-chain program for those raw materials and other ingredients (see 21 CFR § 117.405(a)(1)). The supply-chain program must include using approved suppliers and conducting supplier verification activities (see 21 CFR § 117.410). We note that you had a receiving procedure, “Receiving Raw Materials Document No: SOP-101,\" but it did not address the use of approved suppliers (see 21 CFR 117.415(a)(1)), and you did not approve suppliers.\n\nYour response stated that you have included mycotoxins in your hazard analysis, that your suppliers will include mycotoxins as part of the COAs they send to you, and if their COAs do not include mycotoxin results, they will send you a letter of guarantee (b)(4). However, you did not provide an updated hazard analysis, receiving procedure, or implementation records. Also, note that an (b)(4) guarantee alone would not be an adequate verification activity to ensure that a supplier is controlling the hazard of mycotoxins because it does not include, among other things, actual analytical results from sampling and testing.\n\nCurrent Good Manufacturing Practice (21 CFR Part 117, Subpart B):\n\n2. You did not store or transport food, including ingredients, under conditions that protect against allergen cross-contact to comply with 21 CFR 117.93. Specifically, on March 1, 2022, in the finished product walk-in refrigerator, FDA investigators observed the storage of finished, unpackaged 10” cakes. The cakes were stored on racks with (b)(4) shelving. Cakes with coconut shavings (coconut allergen) were observed stored above lemon cakes that did not contain coconut or other tree nuts. FDA investigators also observed cake toppings stored in individual plastic trays, approximately (b)(4) tall, on a rolling speed rack. Each topping had a loose piece of parchment paper placed on top it. The tray of chopped walnuts ( an allergen) was in the middle of the rack, stored above other non-nut containing toppings such as Oreo crumbles, rainbow sprinkles, red velvet cake crumbles, and yellow cake crumbles.\n\nYour response stated that you have a dedicated rolling rack for allergens and that cakes that contain allergens must be fully packaged upon completion; however, you have not provided any documentation that these corrective actions have been implemented. We have reached out to you requesting supporting documentation and have not received a response to date.\n\nMisbranding\n\n1. Your Blueberry Coffee Cake and Carrot Cake 10” products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. 343(i)(2)] because they are fabricated from two or more ingredients and the labels fail to declare the common or usual name of each ingredient, as required under 21 CFR 101.4. For example:\n\na. Your Blueberry Coffee Cake:\n\ni. The labels fail to declare (b)(4), an ingredient in your blueberry filling ingredient.\n\nii. The label does not bear the statement: “(b)(4)” as required by 21 CFR 172.804(d)(2).\n\niii. The ingredients “Syrus” and “Fondandt” are misspelled, and the flour ingredient “flour unbleached prepared flour” is not an appropriate declaration for a flour ingredient.\n\nb. Your Apple Coffee Cake:\n\ni. The ingredients “Shortening Hydrogenated Soybean & Cottonseed,” “Flourenhanced” are not the appropriate common or usual names for these ingredients as required under 21 CFR 101.4(a). The terms “Artifical,” “USF&D,” “Syrus,” “Fondandt,” “Riboflavor,” and “Propul” are misspelled.\n\nc. Your Carrot Cake 10” label lists cream cheese and its subingredients, which is not used in the product, but fails to list the ingredients in the milk and cheese culture blend that is used in the product. The requirement to list these component ingredients (or “sub-ingredients”) may be met by either parenthetically listing the component ingredients after the common or usual name of the main ingredient, or by listing the component ingredients without listing the ingredient itself. Under the first alternative, the component ingredients must be listed in descending order of predominance within the multi-component ingredient; and under the second alternative, the component ingredients must be listed in descending order of predominance in the finished food.\n\nd. Your Custard Bundt Cake label lists the ingredient “N&A Flavor,” which is not the appropriate common or usual name of an ingredient, as required by 21 CFR 101.4(a).\n\n2. Your Custard Bundt Cakes, Paczki, and Coffee Cakes are misbranded within the meaning of section 403(q) of the Act [21 U.S.C. §343(q)] because they do not comply with the requirements in 21 CFR 101.9. Specifically:\n\na. Your Custard Bundt Cake:\n\ni. The serving size is listed as 1 serving (136g). The appropriate Reference Amount Customarily Consumed Per Eating Occasion (RACC) for the product is 80 g\u002Ffractional slice for large discrete units in accordance with 21 CFR 101.12(b) – Table 2 – Medium weight cakes.\n\nii. The serving size is not expressed in common household measures as required by 21 CFR 101.9(b)(7).\n\nb. Your Cheese Paczki, Blueberry Coffee Cake, and Apple Coffee Cake labels fail to bear nutrition information; i.e., a Nutrition Facts label, as required by 21 CFR 101.9(a). Your firm may qualify for a Small Business Nutrition Labeling Exemption, but as of 6\u002F27\u002F2022, your firm has not filed for the exemption.\n\n3. Your Custard Bundt Cakes are misbranded within the meaning of section 403(k) of the Act [21 U.S.C. §343(k)]. Specifically, the label declares the ingredients sodium benzoate and potassium sorbate, which are chemical preservatives in accordance with 21 CFR 184.1733 and 182.3640, respectively, and the descriptor of the function of these two ingredients is missing. In accordance with 21 CFR 101.22(j), a food to which a chemical preservative(s) is added must include a separate description of its function, e.g., “preservative”, “to retard spoilage”, “a mold inhibitor”, “to help protect flavor” or “to promote color retention”.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to do so may result in legal action including, without limitation, seizure and injunction.\n\nWe also offer the following comment for your Custard Bundt cake label: we note that as a fabricated food, most sugars would not be considered naturally occurring; almost all sugars would be added sugars.\n\nIn your Ingredient statement the first ingredient is sugar, and the Nutrition Facts Label’s added sugar declaration states “37g Total Sugars” but “\u003C 1g Added Sugars.” Information about food labeling, including nutrition labeling and nutrition labeling exemptions, can be found at the following link: https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-labeling-nutrition.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act or that you have complied with FDA regulations, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Lauren Crivellone, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov or at 550 West Jackson Boulevard, Chicago, IL 60661. You may reach Ms. Crivellone at 312-206-5264 or via email at Lauren.Crivellone @fda.hhs.gov if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nDivision East 6","Third Synthesis Inc., dba Chicago Sweet Connections, Inc.","third-synthesis-inc-dba-chicago-sweet-connections-inc-633453-09062022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthird-synthesis-inc-dba-chicago-sweet-connections-inc-633453-09062022","2026-10-26T08:10:11.643576+00:00","Warning Letter","Closed Out","2022-11-08","633453","Food & Beverages","2023-06-02","Division of Human and Animal Food Operations East VI","Anthanasios Kailis","2026-08-20T01:27:32.525+00:00","VIA EMAIL WITH READ RECEIPT","2022-09-06",{"id":35,"raw":36,"subject":42,"body_html":43,"body_text":44,"firm_name":45,"letter_id":46,"created_at":47,"fei_number":20,"letter_url":48,"updated_at":49,"action_type":23,"case_status":50,"posted_date":51,"marcs_cms_no":52,"product_type":53,"closeout_date":20,"issuing_office":40,"recipient_name":54,"body_fetched_at":55,"delivery_method":56,"recipient_title":20,"reference_number":20,"action_taken_date":57,"medical_device_id":20,"response_letter_date":20},3231,[37,38,39,40,41,13,13,13],"\u003Ctime datetime=\"2021-08-03T13:20:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-06T04:00:00Z\">07\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsyntec-pharma-corp-612765-07062021\">Syntec Pharma Corp \u003C\u002Fa>","Office of Pharmaceutical Quality Operations Division I","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Yongsheng Wilson Jiao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Syntec Pharma Corp \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>96 Gazza Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Farmingdale\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11735\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL # 612765\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 6, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Jiao:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Syntec Pharma Corp., FEI 3010057717, located at 96 Gazza Boulevard, Farmingdale, New York 11735, from October 7 to October 28, 2020.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B). Your receipt in interstate commerce of adulterated drugs, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c).\u003C\u002Fp>\n\n\u003Cp>We reviewed your December 4, 2020, response to our Form FDA 483 in detail, and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to perform repackaging, relabeling, or holding of API under appropriate CGMP to avoid mix-ups and loss of API identity or purity.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to have adequate controls to prevent cross-contamination between API. Your functions included receipt, storage, weighing, repackaging, and relabeling of API in the same room using non-dedicated equipment and without appropriate procedures.\u003C\u002Fp>\n\n\u003Cp>During the inspection you initially stated that you did not repackage any highly potent API. However, our review of your records found that you charged your customer for repackaging lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;of Lomustine, a cytotoxic chemotherapy agent. After this was brought to your attention, you acknowledged that you occasionally perform repackaging, but could not remember the specific Lomustine repackaging activity. This repackaging activity lacked basic documentation of the operation, including a batch record and equipment use log.\u003C\u002Fp>\n\n\u003Cp>In addition, you acknowledged that you inappropriately stored Lomustine and human chorionic gonadotrophin (HCG) at room temperature, instead of refrigeration as required by the manufacturers’ certificates of analysis (COA) to prevent degradation.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you kept weed killer, engine antifreeze coolant, and dry wall repair products in the same room where you stored your API and packaging components. You also comingled personal food items and unidentified products in unlabeled aluminum bags in the refrigerator where you stored your API and chemicals.\u003C\u002Fp>\n\n\u003Cp>The drugs distributed by your firm were at risk for contamination and other hazards to drug safety because you failed to appropriately design your facility, establish effective procedures, maintain records of your activities, and implement robust controls.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you will divide the pharmaceutical storage area into four sections by using a separate shelf for each of the following categories: cytotoxic compounds, beta-lactam, other potent compounds, and other API.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You failed to identify the risks associated with the drugs you handled, and to provide an appropriate corrective action and preventive action (CAPA) plan to ensure the remediations necessary to prevent cross-contamination and mix-ups.\u003C\u002Fp>\n\n\u003Cp>FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document \u003Cem>Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\u002Fem> for guidance regarding CGMP for the manufacture of API at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>For additional information, please also refer to our guidance for industry, \u003Cem>Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination\u003C\u002Fem>, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F79971\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F79971\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you have temporarily ceased your repackaging operations.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• An independent retrospective risk assessment to determine whether any API distributed by your firm were contaminated or label mix-ups may have occurred.\u003C\u002Fp>\n\n\u003Cp>• An independent assessment of your facilities, equipment, processes, and materials to determine suitability for their intended use in the manufacture of all drugs. Provide a report that summarizes all inadequate conditions and practices identified by the qualified consultant, along with CAPAs and associated timelines for completion.\u003Cbr>\n\u003Cbr>\n• A comprehensive plan for segregation if you intend to manipulate (e.g., open, sample, weigh, transfer) any beta-lactam or potent compounds. More specifically:\u003Cbr>\n&nbsp; &nbsp; o For beta-lactam API, provide a detailed CAPA that includes, but is not limited to, a facility that is completely and comprehensively separated from the facility where non-beta-lactam API may be exposed.\u003Cbr>\n&nbsp; &nbsp; o For highly potent API, provide an appropriate CAPA that ensures containment for these API to prevent cross-contamination and other safety hazards. Include appropriate design and control provisions related to equipment, air systems, rooms, and procedures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to adequately establish written procedures for cleaning equipment and its release for use in manufacture of API and validate written procedures for the cleaning and maintenance of equipment.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish adequate written procedures for cleaning non-dedicated production equipment used for your API, some of which were highly potent. In addition, you failed to document the usage and cleaning of repackaging equipment. For example, you did not document equipment used or whether cleaning was performed after repackaging a cytotoxic drug, Lomustine (lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>), on or around April 9, 2020.\u003C\u002Fp>\n\n\u003Cp>During the inspection, you stated that the laundry detergent “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” was used to clean the ventilation hood, utensils (stainless steel spoons), and balances. You failed to utilize an appropriate cleaning agent and to conduct cleaning validation studies to demonstrate that your cleaning agent and procedures were effective.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that “Only small tools and equipment were used for these operations, and these tools were visually clean before use. Thus, we believe the risk of contamination of any materials in the market is exceedingly small.” Your response is inadequate because you did not provide compelling evidence to support that cross-contamination has not occurred for your APIs that have been distributed. For example, there were no equipment use logs or records to show when or how cleaning may have occurred.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• An independent risk assessment to determine the effect of inadequate cleaning practices on all potentially affected lots of API you distributed. Specify what actions you will take, such as notifying customers and recalling products, if your risk assessment indicates that your drugs may be compromised by your inadequate cleaning procedures.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive plan including your cleaning validation strategy, procedures, protocols, and study timeline.\u003C\u002Fp>\n\n\u003Cp>• An appropriate cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003Cbr>\n\u003Cbr>\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cp>• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure of your quality unit to exercise its responsibility to ensure the API manufactured at your facility are in compliance with CGMP.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked adequate quality unit (QU) oversight for the manufacture of your API. For example, your QU failed to:\u003C\u002Fp>\n\n\u003Cp>• Perform adequate testing and approve the results for your API prior to their release and distribution. You did not perform identity tests for your API to ascertain their quality. You relied solely on your supplier’s COA without establishing the reliability of the suppliers’ analyses through appropriate qualification. For example, you released Oxytocin lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were tested and found to be super-potent by your customer.\u003C\u002Fp>\n\n\u003Cp>• Ensure that there was stability data to support retest or expiration dates, as well as storage conditions, of API (e.g., lomustine; azelaic acid) when you repackaged them into different container-closure systems from their original ones.\u003C\u002Fp>\n\n\u003Cp>• Establish specifications for the API that you received.\u003C\u002Fp>\n\n\u003Cp>• Establish adequate written procedures for your API receiving, release, and distribution activities.\u003C\u002Fp>\n\n\u003Cp>• Establish and approve master production instructions and have batch production records for every lot of API manufactured (e.g., repacking, relabeling) at your facility.\u003C\u002Fp>\n\n\u003Cp>• Establish adequate procedures for CAPA, change control, and investigations (e.g., out-of-specification results, non-conformances, complaints).\u003C\u002Fp>\n\n\u003Cp>In your response, you provided a recently established procedure for receipt, storage, and release of your incoming materials. You stated that you will reject or approve your incoming materials based on whether a manufacturer reports passing their specifications on a COA.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you did not provide any CAPA for establishing specifications that will be used to evaluate and release each lot of your incoming API, containers, and closures. You also failed to provide details of your supplier qualification program.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you implemented a procedure for good documentation practices. However, you have not established and provided the master production instructions for future API manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fp>\n\n\u003Cp>• Master production instructions for future manufacturing operations (e.g., opening, sampling, weighing, transfer, repackaging, relabeling), and the first five executed batch records if you resume your operations.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive independent review to determine whether materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fp>\n\n\u003Cp>• Stability studies to support retest or expiration dates of each API that are repackaged into different container-closure systems from their original ones. The studies should include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o Stability-indicating methods\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>\n&nbsp; &nbsp; o All procedures that describe these and other elements of your remediated stability program\u003C\u002Fp>\n\n\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that will be used to test the drugs you distribute.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Receipt of Adulterated Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed a list of your suppliers and noted that all drug products from three (3) of your API suppliers were subject to an import alert at the time you imported drugs from these firms. Drugs from two of the API suppliers used by your firm were listed on import alert IA 66-40 for the supplier’s failure to conform to current good manufacturing practice within the meaning of section 501(a)(2)(B). Drugs from one API supplier used by your firm were listed on IA 99-32 for the supplier’s conduct in delaying, denying, or limiting FDA inspections of foreign facilities or providing reasonable access to FDA's inspectional personnel. Additionally, the FDA has issued warning letters to two of your API suppliers explaining that the issues related to CGMP compliance cause the drugs to be adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B). Your receipt in interstate commerce of adulterated drugs and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c).\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cp>• All drug products from \u003Cstrong>(b)(4)\u003C\u002Fstrong> have been listed on FDA IA 66-40 since \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and they remain on import alert at this time. On \u003Cstrong>(b)(4)\u003C\u002Fstrong> received a warning letter from the FDA for failure to comply with CGMPs. Your firm imported multiple lots of Nitrofurantoin manufactured on June 24 and October 21, 2019 by this manufacturer and distributed the drug to your customer from August 16 to November 18, 2019.\u003C\u002Fp>\n\n\u003Cp>• All drug products from \u003Cstrong>(b)(4)\u003C\u002Fstrong> have been listed on FDA IA 66-40 since \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and they remain on import alert at this time. On \u003Cstrong>(b)(4)\u003C\u002Fstrong> received a warning letter from the FDA for failure to comply with CGMPs. Your firm imported Pimobendan EP (European Pharmacopeia) manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> by this manufacturer and distributed the drug to your customer on May 15, 2019.\u003C\u002Fp>\n\n\u003Cp>• All drug products from \u003Cstrong>(b)(4)\u003C\u002Fstrong> have been listed on IA 99-32 since \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and they remain on import alert at this time. Your firm imported multiple lots of Estriol USP (United States Pharmacopeia) manufactured on August 3, 2017, June 9 and October 10, 2018 by this manufacturer, and distributed the drug to your customer from February 21, 2018 to February 26, 2019.\u003C\u002Fp>\n\n\u003Cp>You are responsible for ensuring that the drugs you distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up-to-date information regarding import alerts can be found at the following FDA website: \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems Guidance\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We strongly recommend engaging a consultant qualified to thoroughly evaluate your entire operation to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to suspend manufacturing of drugs at this facility. In response to this letter, clarify whether you intend to conduct any operations at this facility in the future. If you plan to resume drug operations, notify this office prior to resuming these activities.\u003C\u002Fp>\n\n\u003Cp>In addition, if you decide to transfer your ownership, contract out any processes, or move to a new location, notify this office prior to resuming your operations.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\n\n\u003Cp>Correct any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any deviations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to orapharm1_responses@fda.hhs.gov. Your written notification should refer to the Warning Letter number above (#612765).\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Nancy Scheraga and Emmanuel Ramos, Compliance Officers, at Nancy.Scheraga@fda.hhs.gov and Emmanuel.Ramos@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Diana Amador-Toro\u003Cbr>\nProgram Division Director\u002FDistrict Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations\u003Cbr>\nDivision I\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nEmail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Yongsheng Wilson Jiao\n\nRecipient Title\n\nChief Executive Officer\n\nSyntec Pharma Corp\n\n96 Gazza Boulevard\n\nFarmingdale, NY 11735\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations Division I\n\nUnited States\n\nWARNING LETTER\n\nWL # 612765\n\nJuly 6, 2021\n\nDear Mr. Jiao:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Syntec Pharma Corp., FEI 3010057717, located at 96 Gazza Boulevard, Farmingdale, New York 11735, from October 7 to October 28, 2020.\n\nThis warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). Your receipt in interstate commerce of adulterated drugs, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c).\n\nWe reviewed your December 4, 2020, response to our Form FDA 483 in detail, and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific deviations including, but not limited to, the following.\n\n1. Failure to perform repackaging, relabeling, or holding of API under appropriate CGMP to avoid mix-ups and loss of API identity or purity.\n\nYour firm failed to have adequate controls to prevent cross-contamination between API. Your functions included receipt, storage, weighing, repackaging, and relabeling of API in the same room using non-dedicated equipment and without appropriate procedures.\n\nDuring the inspection you initially stated that you did not repackage any highly potent API. However, our review of your records found that you charged your customer for repackaging lot (b)(4) of Lomustine, a cytotoxic chemotherapy agent. After this was brought to your attention, you acknowledged that you occasionally perform repackaging, but could not remember the specific Lomustine repackaging activity. This repackaging activity lacked basic documentation of the operation, including a batch record and equipment use log.\n\nIn addition, you acknowledged that you inappropriately stored Lomustine and human chorionic gonadotrophin (HCG) at room temperature, instead of refrigeration as required by the manufacturers’ certificates of analysis (COA) to prevent degradation.\n\nFurthermore, you kept weed killer, engine antifreeze coolant, and dry wall repair products in the same room where you stored your API and packaging components. You also comingled personal food items and unidentified products in unlabeled aluminum bags in the refrigerator where you stored your API and chemicals.\n\nThe drugs distributed by your firm were at risk for contamination and other hazards to drug safety because you failed to appropriately design your facility, establish effective procedures, maintain records of your activities, and implement robust controls.\n\nIn your response, you stated that you will divide the pharmaceutical storage area into four sections by using a separate shelf for each of the following categories: cytotoxic compounds, beta-lactam, other potent compounds, and other API.\n\nYour response is inadequate. You failed to identify the risks associated with the drugs you handled, and to provide an appropriate corrective action and preventive action (CAPA) plan to ensure the remediations necessary to prevent cross-contamination and mix-ups.\n\nFDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\n\nFor additional information, please also refer to our guidance for industry, Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F79971\u002Fdownload.\n\nWe acknowledge that you have temporarily ceased your repackaging operations.\n\nIn response to this letter, provide:\n\n• An independent retrospective risk assessment to determine whether any API distributed by your firm were contaminated or label mix-ups may have occurred.\n\n• An independent assessment of your facilities, equipment, processes, and materials to determine suitability for their intended use in the manufacture of all drugs. Provide a report that summarizes all inadequate conditions and practices identified by the qualified consultant, along with CAPAs and associated timelines for completion.\n\n• A comprehensive plan for segregation if you intend to manipulate (e.g., open, sample, weigh, transfer) any beta-lactam or potent compounds. More specifically:\n\no For beta-lactam API, provide a detailed CAPA that includes, but is not limited to, a facility that is completely and comprehensively separated from the facility where non-beta-lactam API may be exposed.\n\no For highly potent API, provide an appropriate CAPA that ensures containment for these API to prevent cross-contamination and other safety hazards. Include appropriate design and control provisions related to equipment, air systems, rooms, and procedures.\n\n2. Failure to adequately establish written procedures for cleaning equipment and its release for use in manufacture of API and validate written procedures for the cleaning and maintenance of equipment.\n\nYour firm failed to establish adequate written procedures for cleaning non-dedicated production equipment used for your API, some of which were highly potent. In addition, you failed to document the usage and cleaning of repackaging equipment. For example, you did not document equipment used or whether cleaning was performed after repackaging a cytotoxic drug, Lomustine (lot (b)(4)), on or around April 9, 2020.\n\nDuring the inspection, you stated that the laundry detergent “(b)(4)” was used to clean the ventilation hood, utensils (stainless steel spoons), and balances. You failed to utilize an appropriate cleaning agent and to conduct cleaning validation studies to demonstrate that your cleaning agent and procedures were effective.\n\nIn your response, you stated that “Only small tools and equipment were used for these operations, and these tools were visually clean before use. Thus, we believe the risk of contamination of any materials in the market is exceedingly small.” Your response is inadequate because you did not provide compelling evidence to support that cross-contamination has not occurred for your APIs that have been distributed. For example, there were no equipment use logs or records to show when or how cleaning may have occurred.\n\nIn response to this letter, provide:\n\n• An independent risk assessment to determine the effect of inadequate cleaning practices on all potentially affected lots of API you distributed. Specify what actions you will take, such as notifying customers and recalling products, if your risk assessment indicates that your drugs may be compromised by your inadequate cleaning procedures.\n\n• A comprehensive plan including your cleaning validation strategy, procedures, protocols, and study timeline.\n\n• An appropriate cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n3. Failure of your quality unit to exercise its responsibility to ensure the API manufactured at your facility are in compliance with CGMP.\n\nYour firm lacked adequate quality unit (QU) oversight for the manufacture of your API. For example, your QU failed to:\n\n• Perform adequate testing and approve the results for your API prior to their release and distribution. You did not perform identity tests for your API to ascertain their quality. You relied solely on your supplier’s COA without establishing the reliability of the suppliers’ analyses through appropriate qualification. For example, you released Oxytocin lots (b)(4) and (b)(4) that were tested and found to be super-potent by your customer.\n\n• Ensure that there was stability data to support retest or expiration dates, as well as storage conditions, of API (e.g., lomustine; azelaic acid) when you repackaged them into different container-closure systems from their original ones.\n\n• Establish specifications for the API that you received.\n\n• Establish adequate written procedures for your API receiving, release, and distribution activities.\n\n• Establish and approve master production instructions and have batch production records for every lot of API manufactured (e.g., repacking, relabeling) at your facility.\n\n• Establish adequate procedures for CAPA, change control, and investigations (e.g., out-of-specification results, non-conformances, complaints).\n\nIn your response, you provided a recently established procedure for receipt, storage, and release of your incoming materials. You stated that you will reject or approve your incoming materials based on whether a manufacturer reports passing their specifications on a COA.\n\nYour response is inadequate because you did not provide any CAPA for establishing specifications that will be used to evaluate and release each lot of your incoming API, containers, and closures. You also failed to provide details of your supplier qualification program.\n\nWe acknowledge that you implemented a procedure for good documentation practices. However, you have not established and provided the master production instructions for future API manufacturing operations.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n• Master production instructions for future manufacturing operations (e.g., opening, sampling, weighing, transfer, repackaging, relabeling), and the first five executed batch records if you resume your operations.\n\n• A comprehensive independent review to determine whether materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• Stability studies to support retest or expiration dates of each API that are repackaged into different container-closure systems from their original ones. The studies should include, but not be limited to:\n\no Stability-indicating methods\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\no All procedures that describe these and other elements of your remediated stability program\n\n• A summary of your program for qualifying and overseeing contract facilities that will be used to test the drugs you distribute.\n\nReceipt of Adulterated Drugs\n\nWe reviewed a list of your suppliers and noted that all drug products from three (3) of your API suppliers were subject to an import alert at the time you imported drugs from these firms. Drugs from two of the API suppliers used by your firm were listed on import alert IA 66-40 for the supplier’s failure to conform to current good manufacturing practice within the meaning of section 501(a)(2)(B). Drugs from one API supplier used by your firm were listed on IA 99-32 for the supplier’s conduct in delaying, denying, or limiting FDA inspections of foreign facilities or providing reasonable access to FDA's inspectional personnel. Additionally, the FDA has issued warning letters to two of your API suppliers explaining that the issues related to CGMP compliance cause the drugs to be adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B). Your receipt in interstate commerce of adulterated drugs and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c).\n\nFor example:\n\n• All drug products from (b)(4) have been listed on FDA IA 66-40 since (b)(4), and they remain on import alert at this time. On (b)(4) received a warning letter from the FDA for failure to comply with CGMPs. Your firm imported multiple lots of Nitrofurantoin manufactured on June 24 and October 21, 2019 by this manufacturer and distributed the drug to your customer from August 16 to November 18, 2019.\n\n• All drug products from (b)(4) have been listed on FDA IA 66-40 since (b)(4), and they remain on import alert at this time. On (b)(4) received a warning letter from the FDA for failure to comply with CGMPs. Your firm imported Pimobendan EP (European Pharmacopeia) manufactured on (b)(4) by this manufacturer and distributed the drug to your customer on May 15, 2019.\n\n• All drug products from (b)(4) have been listed on IA 99-32 since (b)(4), and they remain on import alert at this time. Your firm imported multiple lots of Estriol USP (United States Pharmacopeia) manufactured on August 3, 2017, June 9 and October 10, 2018 by this manufacturer, and distributed the drug to your customer from February 21, 2018 to February 26, 2019.\n\nYou are responsible for ensuring that the drugs you distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up-to-date information regarding import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\n\nQuality Systems Guidance\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nWe strongly recommend engaging a consultant qualified to thoroughly evaluate your entire operation to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nDrug Production Suspended\n\nWe acknowledge your commitment to suspend manufacturing of drugs at this facility. In response to this letter, clarify whether you intend to conduct any operations at this facility in the future. If you plan to resume drug operations, notify this office prior to resuming these activities.\n\nIn addition, if you decide to transfer your ownership, contract out any processes, or move to a new location, notify this office prior to resuming your operations.\n\nConclusion\n\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\n\nCorrect any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any deviations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to orapharm1_responses@fda.hhs.gov. Your written notification should refer to the Warning Letter number above (#612765).\n\nIf you have questions regarding the contents of this letter, please contact Nancy Scheraga and Emmanuel Ramos, Compliance Officers, at Nancy.Scheraga@fda.hhs.gov and Emmanuel.Ramos@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDiana Amador-Toro\n\nProgram Division Director\u002FDistrict Director\n\nOffice of Pharmaceutical Quality Operations\n\nDivision I","Syntec Pharma Corp","syntec-pharma-corp-612765-07062021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsyntec-pharma-corp-612765-07062021","2026-10-26T08:10:09.264123+00:00","Issued","2021-08-03","612765","Drugs","Mr. Yongsheng Wilson Jiao","2026-08-20T02:44:22.202+00:00","Email","2021-07-06",{"id":59,"raw":60,"subject":65,"body_html":66,"body_text":67,"firm_name":68,"letter_id":69,"created_at":70,"fei_number":20,"letter_url":71,"updated_at":72,"action_type":23,"case_status":50,"posted_date":73,"marcs_cms_no":74,"product_type":53,"closeout_date":20,"issuing_office":64,"recipient_name":75,"body_fetched_at":76,"delivery_method":77,"recipient_title":20,"reference_number":20,"action_taken_date":78,"medical_device_id":20,"response_letter_date":20},1610,[61,62,63,64,65,13,13,13],"\u003Ctime datetime=\"2024-02-13T14:20:00Z\">02\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-07T05:00:00Z\">02\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynthetix-inc-dba-helix-chemical-supply-668918-02072024\">Synthetix Inc. DBA Helix Chemical Supply\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Matthew Lucks\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Synthetix Inc. DBA Helix Chemical Supply\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>558 Grand Concourse Suite 279\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bronx\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10451\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@helixchem.co\"> info@helixchem.co\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 7, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 668918\u003C\u002Fp>\n\n\u003Cp>Dear Matthew Lucks:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.helixchem.com in October 2023 and has observed that your website offers “Semaglutide” and “Tirzepatide” products for sale in the United States. As described below, your “Semaglutide” and “Tirzepatide” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 301(d). Furthermore, your “Semaglutide” and “Tirzepatide” products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Despite statements on your product labeling marketing your products for “research use only” and “not for human consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims from the products’ labeling, including as observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>From your website www.helixchem.com:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Semaglutide\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Dose Amounts\u003Cbr>\nEach vial contains:\u003Cbr>\nWeeks 1-4 – 8 doses (reconstituted vial expires after 8 weeks.)\u003Cbr>\nWeeks 5-8 – 8 doses (reconstituted vial expires after 8 weeks.) . . .\u003Cbr>\nSemaglutide is a derivative of the naturally occurring GLP-1, a peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Tirzepatide\u003C\u002Fstrong>\u003Cbr>\n“Dose Amounts\u003Cbr>\nEach vial contains:\u003Cbr>\nWeeks 1-4 – 4 doses\u003Cbr>\nWeeks 5-8 – 2 doses. . .\u003Cbr>\nTirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality.”\u003C\u002Fp>\n\n\u003Cp>From the “Standard Dose Protocol for Tirzepatide Research” document accompanying Tirzepatide:\u003C\u002Fp>\n\n\u003Cp>“If additional glycemic control is needed. . . This is the standard schedule for the medication, Mounjaro.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “Semaglutide” and “Tirzepatide” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “Semaglutide” and “Tirzepatide” products are also misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for their intended use(s). “Adequate directions for use” means directions under which a layman can use a drug safely and for the purposes for which it is intended, 21 C.F.R. 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. 353(b)(1), include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Your “Semaglutide” product is indicated for a condition that is not amenable to self-diagnosis and treatment by a layperson, therefore adequate directions cannot be written such that a layperson can use the product safely for its intended use. In addition, your “Semaglutide” and “Tirzepatide” products are also prescription drugs as defined in section 503(b)(1)(A) of the FD&amp;C Act, 21 U.S.C. 353(b)(1)(A), in light of their toxicity or potential for harmful effects, methods of use, or collateral measures necessary for their use. For these reasons, your “Semaglutide” and “Tirzepatide” products are misbranded under section 502(f)(1) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>The introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of these misbranded drugs is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMatthew Lucks\n\nSynthetix Inc. DBA Helix Chemical Supply\n\n558 Grand Concourse Suite 279\n\nBronx, NY 10451\n\nUnited States\n\ninfo@helixchem.co\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nFebruary 7, 2024\n\nRE: 668918\n\nDear Matthew Lucks:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.helixchem.com in October 2023 and has observed that your website offers “Semaglutide” and “Tirzepatide” products for sale in the United States. As described below, your “Semaglutide” and “Tirzepatide” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 301(d). Furthermore, your “Semaglutide” and “Tirzepatide” products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nDespite statements on your product labeling marketing your products for “research use only” and “not for human consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims from the products’ labeling, including as observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:\n\nFrom your website www.helixchem.com:\n\nSemaglutide\n\n“Dose Amounts\n\nEach vial contains:\n\nWeeks 1-4 – 8 doses (reconstituted vial expires after 8 weeks.)\n\nWeeks 5-8 – 8 doses (reconstituted vial expires after 8 weeks.) . . .\n\nSemaglutide is a derivative of the naturally occurring GLP-1, a peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that Semaglutide may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease.”\n\nTirzepatide\n\n“Dose Amounts\n\nEach vial contains:\n\nWeeks 1-4 – 4 doses\n\nWeeks 5-8 – 2 doses. . .\n\nTirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality.”\n\nFrom the “Standard Dose Protocol for Tirzepatide Research” document accompanying Tirzepatide:\n\n“If additional glycemic control is needed. . . This is the standard schedule for the medication, Mounjaro.”\n\nUnapproved New Drugs\n\nYour “Semaglutide” and “Tirzepatide” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nMisbranded Drugs\n\nYour “Semaglutide” and “Tirzepatide” products are also misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for their intended use(s). “Adequate directions for use” means directions under which a layman can use a drug safely and for the purposes for which it is intended, 21 C.F.R. 201.5. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. 353(b)(1), include those that, because of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Your “Semaglutide” product is indicated for a condition that is not amenable to self-diagnosis and treatment by a layperson, therefore adequate directions cannot be written such that a layperson can use the product safely for its intended use. In addition, your “Semaglutide” and “Tirzepatide” products are also prescription drugs as defined in section 503(b)(1)(A) of the FD&C Act, 21 U.S.C. 353(b)(1)(A), in light of their toxicity or potential for harmful effects, methods of use, or collateral measures necessary for their use. For these reasons, your “Semaglutide” and “Tirzepatide” products are misbranded under section 502(f)(1) of the FD&C Act.\n\nThe introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of these misbranded drugs is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","Synthetix Inc. DBA Helix Chemical Supply","synthetix-inc-dba-helix-chemical-supply-668918-02072024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynthetix-inc-dba-helix-chemical-supply-668918-02072024","2026-10-26T08:10:09.323296+00:00","2024-02-13","668918","Matthew Lucks","2026-08-20T00:18:52.044+00:00","Via Email","2024-02-07",3,{"510k":81,"classification":82,"enforcement":83,"event":84,"event_backfill":85,"pma":86,"warning_letter":87},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]